Mineralocorticoid Receptor Antagonists
The role and adverse effects of mineralocorticoid receptor overactivation in the pathophysiology of heart failure (HF) is wellrecognised. MR antagonists (MRAs) have been tested in HF and shown to be effective in improving outcomes. Steroid-type MRAs spironolactone and eplerenone, have been proven to...
Main Authors: | Ilaria Spoletini, Giuseppe MC Rosano |
---|---|
Format: | Article |
Language: | English |
Published: |
Barcaray International
2019-01-01
|
Series: | International Cardiovascular Forum Journal |
Subjects: | |
Online Access: | https://icfjournal.org/index.php/icfj/article/view/603/pdf |
Similar Items
-
Mineralocorticoid receptor antagonist use following heart failure hospitalization
by: Jason M. Duran, et al.
Published: (2020-04-01) -
Mineralocorticoid receptor antagonists in the treatment of patients with chronic heart failure. Positions in 2015
by: Yu F Osmolovskaya, et al.
Published: (2015-09-01) -
Mineralocorticoid receptor antagonists in the treatment of patients with heart failure after myocardial infarction and those with chronic heart failure
by: S N Tereshchenko, et al.
Published: (2013-12-01) -
Prognostic impact of additional mineralocorticoid receptor antagonists in octogenarian heart failure patients
by: Takuro Abe, et al.
Published: (2020-10-01) -
Mineralocorticoid receptor antagonists: new extended roles in cardio- and nephroprotection
by: A. M. Esayan, et al.
Published: (2018-04-01)